Keymed Biosciences' Unit Signs License Deal for Drug's Commercialization

Like
Comment
Favorite

Keymed Biosciences' Unit Signs License Deal for Drug's Commercialization

MT Newswires Live01-10

Keymed Biosciences' (HKG:2162) unit, Keymed Biosciences (Chengdu), and Timberlyne Therapeutics signed an exclusive out-license agreement for the exclusive right to develop, manufacture, and commercialize CM313 globally, excluding mainland China, Hong Kong, Macau, and Taiwan, according to a Friday filing with the Hong Kong bourse.

The group will receive an upfront payment of $30 million and an equity stake in Timberlyne Therapeutics. It may earn up to $337.5 million in milestone payments based on sales and development goals, plus tiered royalties from Timberlyne's net sales.

CM313 is a specialized antibody that targets CD38, a protein linked to various diseases. It works by triggering the immune system to destroy harmful cells and has shown strong results in treating conditions like Immune Thrombocytopenia, Lupus, advanced Multiple Myeloma, and autoimmune diseases, the filing noted.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2502292883?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-10 13:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502292883","market":"fut","top_or_hot":-1,"title":"Keymed Biosciences' Unit Signs License Deal for Drug's Commercialization","media":"MT Newswires Live","content":"<html><body><p> Keymed Biosciences' (HKG:2162) unit, Keymed Biosciences (Chengdu), and Timberlyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> signed an exclusive out-license agreement for the exclusive right to develop, manufacture, and commercialize CM313 globally, excluding mainland China, Hong Kong, Macau, and Taiwan, according to a Friday filing with the Hong Kong bourse.</p><p>The group will receive an upfront payment of $30 million and an equity stake in Timberlyne Therapeutics. It may earn up to $337.5 million in milestone payments based on sales and development goals, plus tiered royalties from Timberlyne's net sales.</p><p>CM313 is a specialized antibody that targets CD38, a protein linked to various diseases. It works by triggering the immune system to destroy harmful cells and has shown strong results in treating conditions like Immune Thrombocytopenia, Lupus, advanced Multiple Myeloma, and autoimmune diseases, the filing noted.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Biosciences' Unit Signs License Deal for Drug's Commercialization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Biosciences' Unit Signs License Deal for Drug's Commercialization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-10 13:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Keymed Biosciences' (HKG:2162) unit, Keymed Biosciences (Chengdu), and Timberlyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> signed an exclusive out-license agreement for the exclusive right to develop, manufacture, and commercialize CM313 globally, excluding mainland China, Hong Kong, Macau, and Taiwan, according to a Friday filing with the Hong Kong bourse.</p><p>The group will receive an upfront payment of $30 million and an equity stake in Timberlyne Therapeutics. It may earn up to $337.5 million in milestone payments based on sales and development goals, plus tiered royalties from Timberlyne's net sales.</p><p>CM313 is a specialized antibody that targets CD38, a protein linked to various diseases. It works by triggering the immune system to destroy harmful cells and has shown strong results in treating conditions like Immune Thrombocytopenia, Lupus, advanced Multiple Myeloma, and autoimmune diseases, the filing noted.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2502292883","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502292883","pubTimestamp":1736486489,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Keymed Biosciences'  unit, Keymed Biosciences , and Timberlyne Therapeutics signed an exclusive out-license agreement for the exclusive right to develop, manufacture, and commercialize CM313 globally, excluding mainland China, Hong Kong, Macau, and Taiwan, according to a Friday filing with the Hong Kong bourse.The group will receive an upfront payment of $30 million and an equity stake in Timberlyne Therapeutics. It may earn up to $337.5 million in milestone payments based on sales and development goals, plus tiered royalties from Timberlyne's net sales.CM313 is a specialized antibody that targets CD38, a protein linked to various diseases. It works by triggering the immune system to destroy harmful cells and has shown strong results in treating conditions like Immune Thrombocytopenia, Lupus, advanced Multiple Myeloma, and autoimmune diseases, the filing noted.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Keymed Biosciences部门签署药物商业化许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":0.9},"content_text":"Keymed Biosciences' (HKG:2162) unit, Keymed Biosciences (Chengdu), and Timberlyne Therapeutics signed an exclusive out-license agreement for the exclusive right to develop, manufacture, and commercialize CM313 globally, excluding mainland China, Hong Kong, Macau, and Taiwan, according to a Friday filing with the Hong Kong bourse.The group will receive an upfront payment of $30 million and an equity stake in Timberlyne Therapeutics. It may earn up to $337.5 million in milestone payments based on sales and development goals, plus tiered royalties from Timberlyne's net sales.CM313 is a specialized antibody that targets CD38, a protein linked to various diseases. It works by triggering the immune system to destroy harmful cells and has shown strong results in treating conditions like Immune Thrombocytopenia, Lupus, advanced Multiple Myeloma, and autoimmune diseases, the filing noted.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}